According to the most recent statistics provided by Cancer Research UK, lung cancer is the third most common cancer in the UK, with around 49 000 new cases in the UK every year which account for 13% of all new cancer cases.

By Dr F. van Delft, Dr M. Schuurbiers, Dr van den Heuvel and Dr H. van Rossum The development of immunotherapy and other targeted therapies has given rise to significant improvements in the treatment of non-small cell lung cancer. However, some patients do not benefit from these therapies and it is, therefore, important for a […]

by Xijun Min, Dr Yan Li, Liuyan Chen, Chengwei Yao, Dr Xi Qin As a traditional tumour marker for the diagnosis of early primary hepatic carcinoma (PHC), alpha fetoprotein (AFP) has a low positive rate. Serum glypican 3 (GPC3) is a novel biomarker, and the combined examination of GPC3 and AFP will provide a new […]